Centessa Pharmaceuticals PLC
NASDAQ:CNTA

Watchlist Manager
Centessa Pharmaceuticals PLC Logo
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Watchlist
Price: 26.31 USD 4.12% Market Closed
Market Cap: $3.5B

Net Margin

-1 618%
Current
Improving
by 316.1%
vs 3-y average of -1 934.1%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-1 618%
=
Net Income
$-242.7m
/
Revenue
$15m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-1 618%
=
Net Income
$-242.7m
/
Revenue
$15m

Peer Comparison

Country Company Market Cap Net
Margin
UK
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
3.5B USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
389.3B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.3B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
170.5B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.2B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
88.6B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.4B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.4B USD
Loading...

Market Distribution

Lower than 99% of companies in United Kingdom
Percentile
1st
Based on 3 670 companies
1st percentile
-1 618%
Low
-188 120% — 0%
Typical Range
0% — 0.1%
High
0.1% — 10 443.9%
Distribution Statistics
United Kingdom
Min -188 120%
30th Percentile 0%
Median 0%
70th Percentile 0.1%
Max 10 443.9%

Centessa Pharmaceuticals PLC
Glance View

Market Cap
3.5B USD
Industry
Biotechnology

In the burgeoning landscape of biopharmaceutical innovation, Centessa Pharmaceuticals PLC stands out with a distinctive operating model that seeks to streamline the path from discovery to market. Centessa, founded in 2020, uniquely consolidates a range of biotech subsidiaries, each focused on distinct therapeutic areas. This structure enables them to maintain a sharp focus on scientific discovery while sharing corporate functions like operations, finance, and legal services to maximize efficiency. By integrating these companies under a single umbrella, Centessa hopes to mitigate the typical inefficiencies and bureaucratic delays that plague the path from pipeline to patient, driving forward their goal of developing transformative medicines. With an emphasis on nimblenes and productivity, Centessa monetizes its pipeline by advancing its most promising drug candidates through clinical development stages, subsequently seeking partnerships or acquisitions with larger pharmaceutical entities. The company's revenue stream hinges on the successful development and eventual commercialization or licensing of these pioneering therapies, often focusing on complex and challenging medical conditions. By nurturing a diverse portfolio of cutting-edge research programs — spanning areas like oncology, immunology, and rare diseases — Centessa strives to deliver breakthroughs that not only enhance patient lives but also provide substantial returns on investment through strategic collaborations and licensing deals within the pharmaceutical ecosystem.

CNTA Intrinsic Value
0.4 USD
Overvaluation 98%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-1 618%
=
Net Income
$-242.7m
/
Revenue
$15m
What is Centessa Pharmaceuticals PLC's current Net Margin?

The current Net Margin for Centessa Pharmaceuticals PLC is -1 618%, which is above its 3-year median of -1 934.1%.

How has Net Margin changed over time?

Over the last 2 years, Centessa Pharmaceuticals PLC’s Net Margin has increased from -2 204.7% to -1 618%. During this period, it reached a low of -2 362.2% on Sep 30, 2024 and a high of -1 496.4% on Mar 31, 2025.

Back to Top